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Abstract: Background: Intensive care unit-acquired pneumonia (ICU-AP) is a severe complication
in patients admitted to the ICU. Lymphocytopenia is a marker of poor prognosis in patients
with community-acquired pneumonia, but its impact on ICU-AP prognosis is unknown.
We aimed to evaluate whether lymphocytopenia is an independent risk factor for mortality in
non-immunocompromised patients with ICU-AP. Methods: Prospective observational cohort study
of patients from six ICUs of an 800-bed tertiary teaching hospital (2005 to 2016). Results: Of the
473 patients included, 277 (59%) had ventilator-associated pneumonia (VAP). Receiver operating
characteristic (ROC) analysis of the lymphocyte counts at diagnosis showed that 595 cells/mm3 was
the best cut-off for discriminating two groups of patients at risk: lymphocytopenic group (lymphocyte
count <595 cells/mm3, 141 patients (30%)) and non-lymphocytopenic group (lymphocyte count
≥595 cells/mm3, 332 patients (70%)). Patients with lymphocytopenia presented more comorbidities
and a higher sequential organ failure assessment (SOFA) score at the moment of pneumonia
diagnosis. Also, 28-day mortality and 90-day mortality were higher in patients with lymphocytopenia
(28-day: 38 (27%) versus 59 (18%), 90-day: 74 (53%) versus 111 (34%)). In the multivariable model,
<595 cells/mm3 resulted to be an independent predictor for 90-day mortality (Hazard Ratio 1.41;
95% Confidence Interval 1.02 to 1.94). Conclusion: Lymphocytopenia is an independent predictor of
90-day mortality in non-immunocompromised patients with ICU-AP.
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1. Background
Nosocomial pneumonia is one of the most common healthcare-associated infections [1]. It occurs
frequently during hospitalization in intensive care units (ICU), causing severe disease that is associated
with high morbidity, mortality, and healthcare costs [2–4].
ICU-acquired pneumonia (ICU-AP) can develop in patients receiving or not mechanical ventilation
(ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP), respectively) and is
usually observed in patients with severe underlying conditions [5].
Like severe community-acquired pneumonia (CAP) and sepsis, ICU-AP may present marked
immunological changes, with lymphocytopenia being one of the most frequently observed [6–9].
However, the association of lymphocytopenia at the time of diagnosis with mortality has not been
assessed to date.
A previous study by our group showed that patients with CAP and lymphocyte counts
<724 lymphocytes/mm3 had a particular immunological phenotype which affected a third of patients
and was associated with a twofold increase in 30-day mortality risk [10]. Similar results have been
observed in patients with sepsis, in whom decreased lymphocyte counts in the blood were thought to
be secondary to the recruitment of these cells to or their escape from sites of inflammation/infection
and/or to apoptosis, which depletes all types of lymphocyte [11,12].
This study aimed to determine whether a low lymphocyte count at the time of ICU-AP diagnosis
is a predictor of lower survival. We evaluated the association between lymphocyte counts in patients
with ICU-AP and 90-day mortality risk. We also determined the cut-off values for lymphocyte counts
that best predicted 90-day mortality.
2. Materials and Methods
2.1. Design and Patients
This prospective cohort study evaluated patients diagnosed with ICU-AP in six ICUs of an 800-bed
tertiary teaching hospital (Hospital Clinic, Barcelona, Spain), admitted from 2005 to 2016. The six ICUs
comprised a broad range of cases, including medical and surgical patients. The investigators made daily
rounds in the ICUs, and patients were included in the study if they were aged ≥18 years and presented
clinically suspected pneumonia 48 h after ICU admission. Patients with severe immunosuppression
were excluded, such as those receiving solid organ or hematopoietic transplantation or chemotherapy,
those with drug-induced immunosuppression, or those with HIV infections. Only the first episode of
pneumonia in each patient was assessed.
The study was approved by the Institution’s Internal Review Board (Comite Etic d’Investigacio
Clinica, registry number 2009/5427), and written informed consent was obtained from the patients or
their relatives.
2.2. Definition of Pneumonia
Pneumonia was clinically diagnosed in patients who had new or progressive pulmonary infiltrates
on their chest radiographs due to an infectious agent and who had at least two of the following symptoms
or findings: fever (>38 ◦C) or hypothermia (<36 ◦C), leukocytosis (>12,000 cells/mm3) or leukopenia
(<4000 cells/mm3), presence of purulent tracheal secretions, and a decline in oxygenation [2,13,14].
ICU-AP was defined as pneumonia developed after more than 48 h of ICU admission. VAP was
identified in patients who were treated with invasive mechanical ventilation for ≥48 h and had met
the above-mentioned criteria; HAP was identified in patients who developed pneumonia after 48 h of
ICU-admission, not receiving invasive mechanical ventilation.
2.3. Data Collection
All relevant data were collected upon ICU admission and at the onset of pneumonia
from medical records and bedside flow charts, including clinical, laboratory, radiological, and
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microbiological information. Multidrug-resistant pathogens were defined on the basis of consensus [15].
Patient follow-up was extended to death, hospital discharge, or up to 90 days after the diagnosis of
pneumonia. Severity was assessed using the sequential organ failure assessment (SOFA) score [16]
during ICU admission and at ICU-AP diagnosis.
2.4. Antimicrobial Treatment
Initial empiric antibiotic therapy was administered at the attending physician’s discretion. The local
policy and practice were based mainly on a local adaptation of the 2005 ATS/IDSA guidelines [14].
It was also recommended that physicians should base their empiric choices on the local prevalence of
multidrug-resistant (MDR) pathogens. The local policy recommended revising the antibiotic regimen
on the basis of culture results. We considered that patients who received empiric antibiotic treatment
in accordance with the 2005 ATS/IDSA guidelines had been administered appropriate antibiotic
treatment [14].
2.5. Leukocyte and Lymphocyte Quantification
Leukocyte and lymphocyte counts were performed with blood collected in EDTA tubes using the
automatic analyzers available and standard operating procedures approved for clinical use.
2.6. Outcome Measures
The primary outcome measure was all-cause mortality on day 90 after the onset of ICU-AP.
The association of lymphocytopenia with treatment failure was also assessed. Initial response to
treatment was evaluated after 72 h of antimicrobial treatment, as previously described [17].
2.7. Statistical Analysis
Categorical variables are presented as numbers and percentages of patients, while continuous
variables (non-normally distributed data) are presented as medians and interquartile ranges (IQR).
Categorical variables were compared with the chi-square test or Fisher’s exact test, while continuous
variables in the two groups were assessed using the non-parametric Mann–Whitney U test. A receiver
operating characteristic (ROC) curve was constructed to determine the best cut-off point for lymphocyte
counts for predicting 90-day mortality. Youden’s index [18] was defined for all the points along the
ROC curve, and the maximum value of the index was used as a criterion for selecting the optimum
cut-off point. Time to 90-day mortality was analyzed by Kaplan–Meier survival curves and compared
using the Gehan–Breslow–Wilcoxon test. Cox proportional hazards regression analyses [19] were
performed to determine the effect of risk factors on 90-day mortality. First, each risk factor was
tested individually. Finally, factors showing an association in the univariate analyses (p < 0.10) were
incorporated into the multivariable Cox regression model to predict 90-day mortality. The final
selection of the variables was performed using the backward stepwise selection method (likelihood
ratio) (pin < 0.05, pout > 0.10). Lymphocyte counts were corrected using a logarithmic transformation in
order to obtain a normal distribution. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were
calculated. Proportional hazards assumptions were tested with log-minus-log plots. To investigate
the lack of fit of our final model, we evaluated the deviance residuals. The ability of the cut-off value
for lymphocyte counts to predict 90-day mortality was further evaluated by using Cox regression
analysis. The internal validity of the prediction models was assessed using ordinary non-parametric
bootstrapping with 1000 bootstrap samples and bias-corrected, accelerated 95% CIs [20]. Additionally,
in order to incorporate nonlinear effects into the Cox regression model, we expressed the hazard as an
additive Cox model [21,22]. We used restricted cubic regression splines, and curves were constructed
according to degrees of freedom (DF), chosen by Akaike information criteria (df = 4, lowest value).
The level of significance was set at 0.05 (two-tailed). All analyses were performed with the IBM SPSS
Statistics 25.0 software (Armonk, NY, USA) and R 3.5.3 software (Vienna, Austria).
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3. Results
3.1. Participants
Of the 473 patients with ICU-AP included during the study period, 196 (41%) had HAP (Figure 1),
and 277 (59%) had VAP.
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Figure 1. Flowchart. ICU-AP: intensive care unit-acquired pneumonia, VAP: ventilator-associated
pneumonia.
3.2. Patients Clinical Characteristics
The clinical characteristics of the patients with ICU-AP are presented in Table 1, stratified by
the presence of lymphocytopenia (lymphocyte counts <595 cells/mm3). On average, patients with
lymphocytopenia had more comorbidities such as chronic renal failure, respiratory disease, and chronic
liver disease. They were also more likely to be admitted to ICU for hypercapnic respiratory failure or
after surgery and presented more severe disease at the onset of pneumonia with higher SOFA score
and multilobar involvement. The two groups showed similar rates of treatment failure at 72 h.
3.3. Lymphocyte Counts
The median lymphocyte count for the 473 patients with ICU-AP was 821 (528; 1243) cells/mm3.
Following Youden’s index, we selected 595 cells/mm3 as the optimal cut-off point for lymphocyte counts
in relation to 90-day mortality (40% sensitivity, 76% specificity, 52% positive predictive value, 67%
negative predictive value, 1.69 positive likelihood ratio, and 0.79 negative likelihood ratio) (Figure S1
and Table S1). The patients were divided into two groups: lymphocytopenic group (lymphocyte
counts <595 cells/mm3, 141 patients (30%) and non-lymphocytopenic group (lymphocyte counts ≥595
cells/mm3, 332 patients (70%).
3.4. Microbiologic Results of Patients with ICU-AP, According to the Presence of Lymphocytopenia
Microbiological diagnosis was possible in 306 patients (65%), with no differences between patients
with or without lymphocytopenia (97 patients (69%) versus 209 patients (63%), respectively; p = 0.22).
The most common microorganism isolated was Pseudomonas aeruginosa, identified in 99 patients
(32%) and more frequent in patients with lymphocytopenia than in patients without it (41 (42%)
versus 58 (28); p = 0.012) (Table 2). The proportion of appropriate empirical treatment did not differ
between groups (108 patients (80%) in the lymphocytopenic group versus 255 patients (80%) in the
non-lymphocytop nic group; p > 0.99
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Table 1. Patients’ clinical characteristics and outcomes.
Variable LymphocytopenicPatients n = 141
Non-Lymphocytopenic
Patients n = 332 p-Value
Age, years 68 (58; 76) 66 (54; 74) 0.13
Sex, male/female, n 99/42 226/109 0.65
Previous corticosteroid use 26 (20) 30 (10) 0.003
SAPS score at ICU admission 40 (29; 50) 38 (29; 48) 0.49
SOFA score at ICU admission 7 (5; 10) 7 (5; 10) 0.88
Lymphocyte counts at ICU admission, cells/mm3 533 (352; 844) 1005 (659; 1382) <0.001
Co-morbidities
Diabetes mellitus 40 (28) 72 (22) 0.12
Chronic renal failure 19 (13) 26 (8) 0.056
Solid cancer 27 (19) 56 (17) 0.55
Chronic heart disorders 50 (35) 111 (33) 0.67
Chronic lung disease 56 (40) 98 (30) 0.030
COPD 38 (27) 64 (19) 0.063
Chronic liver disease 39 (28) 51 (15) 0.002
Main causes of ICU admission:
Post-operative 20 (14) 78 (23) 0.022
Decreased consciousness 17 (12) 40 (12) >0.99
Hypoxemic respiratory failure 29 (21) 53 (16) 0.23
VAP/HAP 80 (57)/ 61 (31) 197 (59)/ 135 (69) 0.60
Severity of pneumonia assessment
SOFA score at day 1 8 (6; 10) 7 (4; 9) 0.003
Multi-lobar involvement 77 (55) 143 (43) 0.021
ARDS criteria 21 (15) 41 (12) 0.47
Shock at onset of pneumonia 69 (49) 135 (41) 0.050
Laboratory variables at onset of pneumonia
Serum creatinine, mg/dL 1 (0.6; 1.7) 0.9 (0.7; 1.4) 0.19
White blood cell count, L−9 10,500 (7000; 14,200) 13,560 (9555; 18,250) <0.001
Lymphocyte counts, cells/mm3 396 (268; 589) 1045 (793; 1431) <0.001
Outcomes
Treatment failure at 72 h 85 (60) 170 (51) 0.070
28-day mortality 38 (27) 59 (18) 0.024
90-day mortality 74 (53) 111 (34) <0.001
Abbreviations: ARDS, acute respiratory distress syndrome; VAP, ventilator-associated pneumonia; COPD, chronic
obstructive pulmonary disease; CPIS, clinical pulmonary infection score (only for patients with VAP); ICU, intensive
care unit; HAP, hospital-acquired pneumonia; PaO2/FiO2, ratio of partial pressure arterial oxygen to fraction of
inspired oxygen; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment. Data are
presented as number of patients (%) or median (1st quartile; 3rd quartile); p-values calculated by Mann–Whitney U
test, chi-square test, or Fisher’s exact test. Percentages calculated on non-missing data.
Table 2. Microbial aetiology.
Lymphocytopenic
Patients n = 141
Non-Lymphocytopenic
Patients n = 332 p-Value
Microbiological diagnosis 97 (69) 209 (63) 0.22
Staphylococcus aureus 25 (26) 56 (27) 0.851
Streptococcus pneumoniae 6 (4) 11 (6) 0.499
Enterobacteriaceae 20 (21) 71 (34) 0.017
Pseudomonas aeruginosa 41 (43) 58 (28) 0.012
MDR pathogens, n (%) 38 (39) 67 (32) 0.222
P. aeruginosa * 15 (9) 21 (36) 0.440
Methicillin-resistant S. aureus (MRSA) * 5 (20) 22 (39) 0.089
Acinetobacter baumannii * 1 (50) 0 -
MDR Enterobacteriaceae * 8 (40) 14 (20) 0.061
Abbreviations: MDR, multidrug resistant. Data are presented as number of patients (%); p-values calculated by
chi-square test or Fisher’s exact test. Percentages calculated on non-missing data. * Percentage calculated for the
total of each pathogen.
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3.5. Outcomes
Patients with lymphocytopenia presented higher mortality rates at 28- and 90-days after initial
diagnosis (Table 1). Kaplan–Meier curves for 90-day survival according to the presence or absence of
lymphocytopenia are shown in Figure 2.
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Figure 2. Kaplan–Meier survival curves for 90-day mortality in ICU-AP patients in relation to their
lymphocyte counts at diagnosis.
3.6. Analysis of 90-Day Mortality Risk
Significant results from the univariate and multivariable analyses are presented in Table 3.
Multivariable analysis showed that lymphocyte counts <595 cells/mm3 were an independent risk factor
for 90-day survival (HR 1.41, 95% CI, 1.02 to 1.94). Internal validation of the final model showed that
all variables remained significant after bootstrapping, with small 95% CIs for the original coefficients
(Table S2). Other factors associated with 90-day survival in the multivariable analyses were chronic
obstructive pulmonary disease (COPD), chronic liver disease, and use of corticosteroids prior to the
diagnosis of ICU-AP.
Table 3. Cox regression analyses to predict 90-day mortality in patients with ICU-AP.
Univariate a Multivariable b
HR 95% CI p-Value HR 95% CI p-Value
Age (+1 year) 1.02 1.01–1.04 <0.001 1.03 1.01–1.04 <0.001
Liver disease 2.03 1.47–2.81 <0.001 1.78 1.24–2.54 0.002
Chronic pulmonary disease 1.73 1.29–2.32 <0.001 1.60 1.16–2.19 0.004
Corticosteroids before admission 1.85 1.26–2.72 0.002 - - -
Corticosteroids at diagnosis 1.40 1.05–1.87 0.024 1.43 1.04–1.95 0.026
Previous surgery 0.66 0.49–0.89 0.006 - - -
SOFA at diagnosis (+1 point) 1.12 1.07–1.17 <0.001 1.13 1.08–1.18 <0.001
Non-ventilated hospital-acquired pneumonia 1.28 0.96–1.71 0.098 - - -
Appropriate antibiotic treatment 0.61 0.44–0.84 0.0 3 - - -
Lymphocytes (<595 cells/mm3) b 1.83 1.36–2.46 <0.001 1.41 1.02–1.94 0.038
Abbreviations: CI, confid nce interval; HR, hazard ratio. Data are shown as estimated HRs (95% CIs) of the
explanatory variables in the 90-day mortality group. The HR is defined as the ratio of the hazard rates corresponding
to the conditions described by two levels of an explanatory variable (the hazard rate is the risk of death (i.e., the
probability of death), given that the patient has survived up to a specific time). The p-value is based on the null
hypothesis that all HRs relating to an explanatory variable equal unity (no effect). a The variables analyzed in the
univariate analysis were: age, gender, diabetes mellitus, chronic renal disease, neoplasia, chronic cardiovascular
disease, chronic liver disease, chronic pulmonary disease, corticoids before admission, corticoids at diagnosis,
previous surgery, SOFA score, appropriate antibiotic treatment, and ventilator-associated pneumonia. b Optimal
cut-off value to predict 90-day mortality using receiver operating characteristic (ROC) curves.
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Figure 3 provides estimates of the exposure–response function of lymphocyte count on 90-day
survival, using restricted cubic regression splines. We observed a significant non-linear effect of
lymphocyte counts on 90-day survival in crude and adjusted analyses. The increase in the risk of death
due to low lymphocyte count was similar to the cut-off value retrieved from the ROC analysis.
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4. Discussion
In this analysis of a well-characterized cohort of patients with ICU-AP, we found lymphocyte
count to be a predictor of 90-day survival with a non-linear risk. Our results showed that a lymphocyte
count below 595 cells/mm3 at diagnosis was a robust, independent risk factor for 90-day mortality in
these patients.
ICU-AP is a severe complication that may lead to death [23–26]. Several risk factors have been
described for developing this hospital-acquired form of pneumonia. Although the incidences of VAP
and HAP are declining [27–30], they remain important and contribute to the intensive use of antibiotics
and healthcare resources as well as to high mortality rates [30,31]. Despite the differences between the
epidemiology of VAP and HAP, both types of pneumonia can be considered as ICU-AP [5,32].
Identifying risk factors for mortality could help to improve patient care and personalize
treatments [33]. Pneumonia frequently leads to sepsis and induces significant local and systemic
inflammation. Hyper- and hypo-inflammatory responses are observed in patients with sepsis,
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the hypo-inflammatory response presenting with lymphocytopenia or T-cell exhaustion [6].
The lymphocytopenia observed is not classical immunosuppression; however, differences in immune
response with respect to patients with sepsis who died in ICU have been observed [34]. Identifying
different endotypes in patients with sepsis is a major challenge at present [35–37]. A previous
study by our group showed that patients with CAP had a higher risk of mortality if they presented
lymphocytopenia. In CAP, the addition of lymphocytopenia to the CURB-65 score increases the
latter’s accuracy for predicting mortality. The optimal cut-off point for predicting 30-day mortality was
identified as 724 lymphocytes/mm3 in patients with CAP [10]. In the present study, the optimal cut-off
point for predicting 90-day mortality was lower for ICU-AP than for CAP.
A recent study in critically ill patients revealed that patients with CAP and HAP showed similar
inflammatory responses and gene expression profiles [38]. However, patients with HAP exhibited
lower expression levels of the genes involved in the type I interferon signaling pathway and increased
expression of genes associated with cell junctions and cell movement.
The association between low lymphocyte counts and mortality in ICU-AP might lead to the
identification of new therapeutic agents such as drugs that prevent apoptosis, promote cell survival,
or activate T cells (i.e., interleukin-7 or anti-programmed cell death protein 1 antibodies). These
drugs have been shown to reverse the immunosuppression caused by sepsis in animal models [39,40],
and an anti-programmed cell death protein 1 antibody was well tolerated in a phase 1 study [41].
Unfortunately, it is not yet clear whether the presence of low lymphocyte counts has any real impact on
patient survival or whether it is merely a biomarker of disease severity. Nonetheless, using lymphocyte
counts to identify patients at a higher risk of mortality could help to personalize treatments and to
stratify patients by severity in clinical studies.
Other independent predictors of 90-day mortality were COPD, liver disease, and use of
corticosteroids at the time of ICU-AP diagnosis. These findings are consistent with previous publications
by our group [42–44], and, in addition, lymphocytopenia may help to stratify the mortality risk of
populations enrolled in randomized controlled trials designed to explore potential differences in
treatment effects.
Our study has some limitations. First, the study was carried out at a single center in Spain.
However, it involved six different ICUs from the hospital. Second, only ICU patients were included;
thus, the profiles of patients with HAP managed outside the ICU may be different. The major strength
of our study is the large and well-characterized cohort studied.
5. Conclusions
In conclusion, a low lymphocyte count at the moment of diagnosis of ICU-AP increases the risk
to die: presenting with less than 595 cell/mm3 is a predictor of long-term mortality in patients with
this disease. Lymphocyte counting is an inexpensive tool that is widely available in hospitals in both
developing and developed countries and could help to personalize treatment in patients with ICU-AP.
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CAP community-acquired pneumonia
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DF degrees of freedom
HAP hospital-acquired pneumonia
HRs hazard ratios
ICU Intensive care units
ICU-AP ICU-acquired pneumonia
IQR interquartile range
SOFA sequential organ failure assessment
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